Abstract |
We report here the long-term outcome of autologous stem cell transplant in peripheral T-cell lymphoma (PTCL). Forty-three consecutive patients with PTCL diagnosed between 2000 and 2011 were treated with high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) in our center. Diagnoses included PTCL-not otherwise specified (n = 19), anaplastic large cell lymphoma (n = 11), angioimmunoblastic T-cell lymphoma (n = 5), enteropathy-associated T-cell lymphoma (n = 5) and other rare subtypes (n = 3). Thirty-six patients with a median age of 50 years (range 22-65) were transplanted in first response and seven after relapse. After a median follow-up of 63 months, estimated overall survival at 12 years was 40%, progression-free survival at 12 years was 34% and event-free survival at 12 years was 30%. On univariate analysis, age less than 50 years and no B symptoms at diagnosis were significantly associated with prolonged overall and progression-free-survival. HDCT/ASCT for peripheral T-cell lymphoma can lead to long-term survival for patients responding to induction chemotherapy.
|
Authors | Anne Cairoli, Nicolas Ketterer, Stefano Barelli, Michel A Duchosal |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 55
Issue 8
Pg. 1827-31
(Aug 2014)
ISSN: 1029-2403 [Electronic] United States |
PMID | 24138331
(Publication Type: Journal Article)
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Disease Progression
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Lymphoma, T-Cell
(diagnosis, mortality, therapy)
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Recurrence
- Remission Induction
- Transplantation, Autologous
- Treatment Outcome
- Young Adult
|